

# Angelo Corti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2822775/publications.pdf>

Version: 2024-02-01

208  
papers

10,320  
citations

31976

53  
h-index

42399

92  
g-index

210  
all docs

210  
docs citations

210  
times ranked

8816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. <i>Clinica Chimica Acta</i> , 2022, 526, 49-54.	1.1	0
2	A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 846958.	2.8	3
3	Chromogranin A plasma levels predict mortality in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0267235.	2.5	9
4	Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor- $\beta$ . <i>Pharmaceutics</i> , 2022, 14, 1414.	4.5	4
5	The chromogranin A 1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1. <i>Acta Physiologica</i> , 2021, 231, e13570.	3.8	14
6	Breaching the Blood-Brain Tumor Barrier for Tumor Therapy. <i>Cancers</i> , 2021, 13, 2391.	3.7	19
7	Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for $\alpha$ <sup>v</sup> $\beta$ <sup>3</sup> -Integrin Targeting. <i>Frontiers in Chemistry</i> , 2021, 9, 690357.	3.6	2
8	Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. <i>Journal of Nanobiotechnology</i> , 2021, 19, 128.	9.1	13
9	CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. <i>Molecular Medicine</i> , 2021, 27, 129.	4.4	41
10	NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 3813-3824.	4.6	6
11	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658.	5.2	24
12	Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 613582.	2.8	2
13	Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. <i>Small</i> , 2019, 15, e1903462.	10.0	21
14	Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. <i>Annals of the New York Academy of Sciences</i> , 2019, 1455, 34-58.	3.8	64
15	Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. <i>Small</i> , 2019, 15, e1804591.	10.0	34
16	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- $\beta$ in primary CNS lymphoma. <i>Blood</i> , 2019, 134, 252-262.	1.4	43
17	Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity. <i>FASEB Journal</i> , 2019, 33, 7734-7747.	0.5	20
18	Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement. <i>Cancer Research</i> , 2019, 79, 1925-1937.	0.9	9

#	ARTICLE	IF	CITATIONS
19	The Importance of Detail: How Differences in Ligand Structures Determine Distinct Functional Responses in Integrin $\alpha_3\beta_1$ . <i>Chemistry - A European Journal</i> , 2019, 25, 5959-5970.	3.3	10
20	A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients. , 2019, 1, e0044.		10
21	A stapled chromogranin A-derived peptide is a potent dual ligand for integrins $\alpha_6\beta_1$ and $\alpha_8\beta_1$ . <i>Chemical Communications</i> , 2019, 55, 14777-14780.	4.1	5
22	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019, 19, 57-63.	1.1	6
23	Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cells. <i>Cell and Tissue Research</i> , 2019, 376, 51-70.	2.9	11
24	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2171-2181.	7.0	40
25	Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. <i>Diabetes</i> , 2018, 67, 841-848.	0.6	58
26	Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers. <i>Pflügers Archiv European Journal of Physiology</i> , 2018, 470, 199-210.	2.8	36
27	Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. <i>Small</i> , 2018, 14, e1802886.	10.0	23
28	Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to $\alpha_3\beta_1$ without Promoting Integrin Allosteric Activation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7474-7485.	6.4	19
29	Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0196858.	2.5	14
30	Targeting CD13 with Asn-Gly-Arg (NGR) Peptide-Drug Conjugates. , 2017, , 101-122.		5
31	Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion. <i>Cell and Tissue Research</i> , 2017, 368, 487-501.	2.9	24
32	Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. <i>International Journal of Cardiology</i> , 2017, 236, 438-443.	1.7	11
33	Granin-derived peptides. <i>Progress in Neurobiology</i> , 2017, 154, 37-61.	5.7	65
34	Tumor cell-associated immune checkpoint molecules “ Drivers of malignancy and stemness. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 571-583.	7.4	54
35	Glycine <i>N</i> -Methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate Formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. <i>Advanced Functional Materials</i> , 2017, 27, 1701245.	14.9	19
36	Chromogranin A in Endothelial Homeostasis and Angiogenesis. <i>UNIPA Springer Series</i> , 2017, , 83-98.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice. <i>Journal of Endocrinology</i> , 2017, 232, 137-153.	2.6	8
38	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF $\pm$ Expression and Empower Adoptive Cell Therapy for Solid Tumors. <i>Cancer Research</i> , 2017, 77, 658-671.	0.9	30
39	Chromogranin-A production and fragmentation in patients with Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 187.	3.5	21
40	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	4.6	14
41	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	6.4	90
42	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , 2016, 76, 1781-1791.	0.9	24
43	Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2223-2228.	7.1	35
44	NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. <i>Nano Research</i> , 2016, 9, 1393-1408.	10.4	48
45	Regulation of tumor growth by circulating full-length chromogranin A. <i>Oncotarget</i> , 2016, 7, 72716-72732.	1.8	18
46	Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , 2015, 10, 59.	10.8	35
47	Altered Chromogranin A Circulating Levels in Meniere's Disease. <i>Disease Markers</i> , 2015, 2015, 1-6.	1.3	8
48	Chromogranin A: a paradoxical player in angiogenesis and vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 339-348.	5.4	41
49	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. <i>Biomaterials</i> , 2015, 68, 89-99.	11.4	36
50	pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury. <i>Journal of Endocrinology</i> , 2015, 227, 167-178.	2.6	24
51	Effect of chromogranin A-derived vasostatin on laser-induced choroidal neovascularization in the mouse. <i>Acta Ophthalmologica</i> , 2015, 93, e218-22.	1.1	16
52	Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis. <i>Experimental Cell Research</i> , 2015, 330, 1-12.	2.6	17
53	Abstract 4387: Anti-tumor activity of TNF-gold nanodrugs tagged with tumor vasculature-homing peptides containing the NGR or isoDGR motives. <i>Cancer Research</i> , 2015, 75, 4387-4387.	0.9	3
54	Oral direct thrombin inhibition: a double-edged sword?. <i>Heart, Lung and Vessels</i> , 2015, 7, 191-7.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Oxidation-induced Structural Changes of Ceruloplasmin Foster NGR Motif Deamidation That Promotes Integrin Binding and Signaling. <i>Journal of Biological Chemistry</i> , 2014, 289, 3736-3748.	3.4	28
56	TNF- $\alpha$ in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. <i>Rheumatology</i> , 2014, 53, 198-200.	1.9	16
57	Bone marrow-derived CD13 <sup>+</sup> cells sustain tumor progression. <i>Oncolmmunology</i> , 2014, 3, e27716.	4.6	5
58	A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. <i>Oncolmmunology</i> , 2014, 3, e963406.	4.6	23
59	Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads. <i>International Journal of Cancer</i> , 2014, 135, 1265-1276.	5.1	51
60	Abstract 1778: Characterization and anti-tumor functionality of a neuroblastoma-specific peptide, either free or conjugated to nanocarriers. , 2014, , .		0
61	Full-Length Human Chromogranin-A Cardioactivity: Myocardial, Coronary, and Stimulus-Induced Processing Evidence in Normotensive and Hypertensive Male Rat Hearts. <i>Endocrinology</i> , 2013, 154, 3353-3365.	2.8	41
62	Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example. <i>BioDrugs</i> , 2013, 27, 591-603.	4.6	63
63	Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. <i>Journal of Controlled Release</i> , 2013, 170, 233-241.	9.9	41
64	A new chromogranin A-dependent angiogenic switch activated by thrombin. <i>Blood</i> , 2013, 121, 392-402.	1.4	68
65	CgA in heart diseases: more than meets the eye. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 90.	11.4	1
66	Improving Drug Uptake and Penetration into Tumors: Current and Forthcoming Opportunities. <i>Frontiers in Oncology</i> , 2013, 3, 161.	2.8	6
67	CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20717-20722.	7.1	35
68	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MAbs</i> , 2013, 5, 34-46.	5.2	46
69	Selective Imaging of the Angiogenic Relevant Integrins $\alpha_5\beta_1$ and $\alpha_v\beta_3$ . <i>Angewandte Chemie - International Edition</i> , 2013, 52, 11656-11659.	13.8	43
70	Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 49-56.	1.5	6
71	IsoDGR-tagged Albumin: A New $\alpha_v\beta_3$ Selective Carrier for Nanodrug Delivery to Tumors. <i>Small</i> , 2013, 9, 673-678.	10.0	33
72	Abstract 5620: Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract 5617: A new alphaV/beta3 integrin selective carrier for nanodrug delivery to tumors based on isoDGR-tagged albumin.., 2013, , .		0
74	Chromogranin A Regulates Tumor Self-Seeding and Dissemination. <i>Cancer Research</i> , 2012, 72, 449-459.	0.9	27
75	Chromogranin A and the Endothelial Barrier Function. <i>Current Medicinal Chemistry</i> , 2012, 19, 4051-4058.	2.4	18
76	Wonâ€™t you come on in? How to favor lymphocyte infiltration in tumors. <i>Oncolmmunology</i> , 2012, 1, 986-988.	4.6	21
77	Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. <i>Biomarkers</i> , 2012, 17, 430-434.	1.9	8
78	Targeting TNF-Î± to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. <i>Journal of Immunology</i> , 2012, 188, 2687-2694.	0.8	128
79	Tumor Necrosis Factor Î± As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. <i>Journal of Clinical Oncology</i> , 2012, 30, e286-e290.	1.6	79
80	Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance. <i>Intensive Care Medicine</i> , 2012, 38, 1514-1522.	8.2	24
81	Improving drug penetration to curb tumor drug resistance. <i>Drug Discovery Today</i> , 2012, 17, 1139-1146.	6.4	27
82	Chromogranin A and Derived Peptides in Health and Disease. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 347-356.	2.3	76
83	Commentary: Granins, Secretory Granule Biogenesis, and Transport. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 315-316.	2.3	0
84	Chromogranin A binds to Î±vÎ²6-integrin and promotes wound healing in mice. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2791-2803.	5.4	17
85	The N-Terminal Fragment of Chromogranin A, Vasostatin-1 Protects Mice From Acute or Chronic Colitis Upon Oral Administration. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1227-1237.	2.3	12
86	How to improve exposure of tumor cells to drugs â€” Promoter drugs increase tumor uptake and penetration of effector drugs. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 53-68.	13.7	78
87	Targeted Drug Delivery and Penetration Into Solid Tumors. <i>Medicinal Research Reviews</i> , 2012, 32, 1078-1091.	10.5	108
88	Abstract 1414: Regulation of tumor cell trafficking by chromogranin A. , 2012, , .		0
89	Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1128-1134.	1.6	62
90	Processing of chromogranins/secretogranin in patients with diabetic retinopathy. <i>Regulatory Peptides</i> , 2011, 167, 118-124.	1.9	16

#	ARTICLE	IF	CITATIONS
91	The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. <i>Regulatory Peptides</i> , 2011, 168, 10-20.	1.9	15
92	Isoaspartate-dependent molecular switches for integrin $\alpha$ ligand recognition. <i>Journal of Cell Science</i> , 2011, 124, 515-522.	2.0	75
93	The vasostatin $\alpha$ 1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia $\alpha$ driven endothelial cells and regulates tumor neovascularization. <i>FASEB Journal</i> , 2011, 25, 3906-3914.	0.5	34
94	Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 47-59.	2.5	56
95	Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy. <i>Cancer Research</i> , 2011, 71, 5881-5890.	0.9	23
96	Long human <i>CHGA</i> flanking chromosome 14 sequence required for optimal BAC transgenic $\alpha$ rescue of disease phenotypes in the mouse <i>Chga</i> knockout. <i>Physiological Genomics</i> , 2010, 41, 91-101.	2.3	12
97	Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 2107-2118.	5.4	16
98	Chromogranin A and the Tumor Microenvironment. <i>Cellular and Molecular Neurobiology</i> , 2010, 30, 1163-1170.	3.3	45
99	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. <i>Journal of Controlled Release</i> , 2010, 145, 66-73.	9.9	78
100	Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA1-64) in the rat heart. <i>Regulatory Peptides</i> , 2010, 165, 78-85.	1.9	12
101	Chromogranin A and its peptide fragments in tumour biology. <i>Regulatory Peptides</i> , 2010, 164, 20-21.	1.9	0
102	Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment. <i>Clinical Biochemistry</i> , 2010, 43, 1387-1392.	1.9	16
103	Immunomodulatory Agents with Antivasular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. <i>Journal of Oncology</i> , 2010, 2010, 1-8.	1.3	13
104	Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching. <i>Journal of Biological Chemistry</i> , 2010, 285, 9114-9123.	3.4	77
105	Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. <i>European Journal of Cancer</i> , 2010, 46, 198-206.	2.8	50
106	Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF $\alpha$ -elicited endothelial activation. <i>Journal of Leukocyte Biology</i> , 2009, 85, 81-87.	3.3	52
107	Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. <i>Methods in Enzymology</i> , 2009, 465, 225-249.	1.0	13
108	High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 293-295.	0.9	21

#	ARTICLE	IF	CITATIONS
109	Epitope Mapping of Human Chromogranin A by Peptide Microarrays. <i>Methods in Molecular Biology</i> , 2009, 570, 221-232.	0.9	6
110	Vasculature-targeted tumor necrosis factor- $\alpha$ increases the therapeutic index of doxorubicin against prostate cancer. <i>Prostate</i> , 2008, 68, 1105-1115.	2.3	47
111	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. <i>Trends in Immunology</i> , 2008, 29, 235-241.	6.8	32
112	Structural Basis for the Interaction of isoDGR with the RGD-binding Site of $\alpha_5\beta_3$ Integrin. <i>Journal of Biological Chemistry</i> , 2008, 283, 19757-19768.	3.4	93
113	Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor- $\alpha$ . <i>Cancer Research</i> , 2008, 68, 1154-1161.	0.9	45
114	Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN $\alpha$ . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3859-3866.	4.1	25
115	Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. <i>Clinical Cancer Research</i> , 2008, 14, 7320-7329.	7.0	82
116	Isoaspartate-Glycine-Arginine: A New Tumor Vasculature-Targeting Motif. <i>Cancer Research</i> , 2008, 68, 7073-7082.	0.9	71
117	The neovasculature homing motif NGR: more than meets the eye. <i>Blood</i> , 2008, 112, 2628-2635.	1.4	181
118	The vasostatin-1 fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. <i>FASEB Journal</i> , 2007, 21, 3052-3062.	0.5	75
119	Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. <i>European Heart Journal</i> , 2007, 28, 1117-1127.	2.2	160
120	Crucial role of cytoskeleton reorganization in the negative inotropic effect of chromogranin A-derived peptides in eel and frog hearts. <i>Regulatory Peptides</i> , 2007, 138, 145-151.	1.9	21
121	Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H719-H727.	3.2	60
122	Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2007, 110, 845-853.	4.1	38
123	Conversation galante: How the immune and the neuroendocrine systems talk to each other. <i>Autoimmunity Reviews</i> , 2007, 7, 23-29.	5.8	42
124	The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2863-2886.	5.4	185
125	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. <i>Molecular Immunology</i> , 2006, 43, 1509-1518.	2.2	49
126	Post cardiac surgery diaphragmatic spasm successfully treated with gabapentin. <i>International Journal of Cardiology</i> , 2006, 109, 282-283.	1.7	3



#	ARTICLE	IF	CITATIONS
127	Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. <i>Regulatory Peptides</i> , 2006, 134, 30-37.	1.9	40
128	The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. <i>Regulatory Peptides</i> , 2006, 135, 78-84.	1.9	63
129	Characterization of natural vasostatin-containing peptides in rat heart. <i>FEBS Journal</i> , 2006, 273, 3311-3321.	4.7	50
130	Neuroendocrine Modulation Induced by Selective Blockade of TNF- $\alpha$ in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 428-437.	3.8	34
131	Human Recombinant Vasostatin-1 May Interfere with Cell-Extracellular Matrix Interactions. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 305-310.	3.8	6
132	Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. <i>Investigational New Drugs</i> , 2006, 24, 27-36.	2.6	43
133	Recombinant N-terminal fragments of chromogranin A modulate cardiac function of the Langendorff-perfused rat heart. <i>Basic Research in Cardiology</i> , 2006, 101, 43-52.	5.9	66
134	Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. <i>Cancer Research</i> , 2006, 66, 10073-10082.	0.9	215
135	Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor- $\alpha$ . <i>Clinical Cancer Research</i> , 2006, 12, 175-182.	7.0	141
136	Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin. <i>Journal of Biological Chemistry</i> , 2006, 281, 36466-36476.	3.4	176
137	Peptide microarrays for the characterization of antigenic regions of human chromogranin A. <i>Proteomics</i> , 2005, 5, 3600-3603.	2.2	32
138	Targeted Delivery of IFN $\gamma$ to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms. <i>Cancer Research</i> , 2005, 65, 2906-2913.	0.9	87
139	Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colon. <i>Regulatory Peptides</i> , 2005, 130, 42-47.	1.9	17
140	Strategies for Improving the Anti-Neoplastic Activity of TNF by Tumor Targeting. , 2004, 98, 247-264.		11
141	TNF- $\alpha$ Coupled to Membrane of Apoptotic Cells Favors the Cross-Priming to Melanoma Antigens. <i>Journal of Immunology</i> , 2004, 172, 2643-2650.	0.8	28
142	Chromogranin A protects vessels against tumor necrosis factor $\alpha$ -induced vascular leakage. <i>FASEB Journal</i> , 2004, 18, 554-556.	0.5	102
143	Inhibition of Tumor Growth by Intramuscular Injection of cDNA Encoding Tumor Necrosis Factor- $\alpha$ Coupled to NGR and RGD Tumor-Homing Peptides. <i>Human Gene Therapy</i> , 2004, 15, 373-382.	2.7	54
144	Coupling Tumor Necrosis Factor- $\alpha$ with $\alpha$ V Integrin Ligands Improves Its Antineoplastic Activity. <i>Cancer Research</i> , 2004, 64, 565-571.	0.9	134

#	ARTICLE	IF	CITATIONS
145	Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7â€“57 peptide act as cardiostatins on the isolated working frog heart. <i>General and Comparative Endocrinology</i> , 2004, 136, 217-224.	1.8	59
146	Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel ( <i>Anguilla anguilla</i> ): negative inotropy and mechanism of action. <i>General and Comparative Endocrinology</i> , 2004, 139, 20-28.	1.8	64
147	Tumor Vascular Targeting with Tumor Necrosis Factor $\hat{A}$ and Chemotherapeutic Drugs. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 104-112.	3.8	78
148	Production and Characterization of Recombinant Human and Murine TNF. , 2004, 98, 009-022.		7
149	Crucial Role for Interferon $\hat{I}3$ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor $\hat{I}z$ (NGR-TNF) and Doxorubicin. <i>Cancer Research</i> , 2004, 64, 7150-7155.	0.9	66
150	Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis. <i>Current Medicinal Chemistry Immunology, Endocrine &amp; Metabolic Agents</i> , 2004, 4, 161-168.	0.2	8
151	Characterisation of functional biotinylated TNF- $\hat{I}z$ targeted to the membrane of apoptotic melanoma cells. <i>Journal of Immunological Methods</i> , 2003, 276, 79-87.	1.4	6
152	Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. <i>Cancer Research</i> , 2003, 63, 7400-9.	0.9	242
153	Cleavage of Chromogranin A N-terminal Domain by Plasmin Provides a New Mechanism for Regulating Cell Adhesion. <i>Journal of Biological Chemistry</i> , 2002, 277, 45911-45919.	3.4	32
154	Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif. <i>Journal of Biological Chemistry</i> , 2002, 277, 47891-47897.	3.4	159
155	Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. <i>European Heart Journal</i> , 2002, 23, 967-974.	2.2	189
156	Regulation of Endothelial Cell Shape and Barrier Function by Chromogranin A. <i>Annals of the New York Academy of Sciences</i> , 2002, 971, 355-358.	3.8	31
157	Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482.	8.2	206
158	Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482.	8.2	111
159	Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482.	8.2	32
160	Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. <i>Cancer Research</i> , 2002, 62, 867-74.	0.9	217
161	Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. <i>Cancer Research</i> , 2002, 62, 941-6.	0.9	39
162	Roles of tumor necrosis factor p55 and p75 receptors in TNF- $\hat{I}z$ -induced vascular permeability. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 281, C1173-C1179.	4.6	80

#	ARTICLE	IF	CITATIONS
163	Biotinylation Sites of Tumor Necrosis Factor- $\alpha$ Determined by Liquid Chromatography-Mass Spectrometry. <i>Analytical Biochemistry</i> , 2001, 298, 181-188.	2.4	8
164	Structure-Activity Relationships of Chromogranin A in Cell Adhesion. <i>Journal of Biological Chemistry</i> , 2000, 275, 29257-29263.	3.4	70
165	Enhancement of tumor necrosis factor $\alpha$ antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). <i>Nature Biotechnology</i> , 2000, 18, 1185-1190.	17.5	403
166	Antibacterial and Antifungal Activities of Vasostatin-1, the N-terminal Fragment of Chromogranin A. <i>Journal of Biological Chemistry</i> , 2000, 275, 10745-10753.	3.4	144
167	Chromogranin A and Tumor Necrosis Factor- $\alpha$ (TNF) in Chronic Heart Failure. , 2000, 482, 351-359.		50
168	Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor- $\alpha$ . <i>European Heart Journal</i> , 1999, 20, 1503-1513.	2.2	37
169	Vascular attack and immunotherapy: a "two hits" approach to improve biological treatment of cancer. <i>Gene Therapy</i> , 1999, 6, 153-154.	4.5	6
170	Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype. <i>FEBS Letters</i> , 1999, 460, 149-152.	2.8	71
171	Upregulation of p75 Tumor Necrosis Factor Alpha Receptor in <i>Mycobacterium avium</i> -Infected Mice: Evidence for a Functional Role. <i>Infection and Immunity</i> , 1999, 67, 5762-5767.	2.2	13
172	Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?. <i>Progress in Cardiovascular Diseases</i> , 1998, 41, 25-30.	3.1	52
173	Biochemical characterization and crystal structure of a recombinant hen avidin and its acidic mutant expressed in <i>Escherichia coli</i> . <i>FEBS Journal</i> , 1998, 256, 453-460.	0.2	36
174	Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 14339-14346.	3.4	88
175	Chromogranin A Fragments Modulate Cell Adhesion. <i>Journal of Biological Chemistry</i> , 1997, 272, 20835-20843.	3.4	71
176	Tumor necrosis factor $\alpha$ and its receptors in relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1997, 152, 51-61.	0.6	49
177	The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscinigraphy and radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 350-351.	2.1	53
178	Production and Structure Characterization of Recombinant Chromogranin A N-Terminal Fragments (Vasostatins). Evidence of Dimmer-Monomer Equilibria. <i>FEBS Journal</i> , 1997, 248, 692-699.	0.2	44
179	Effect of bench-scale culture conditions on murine IgG heterogeneity. , 1997, 54, 17-25.		11
180	NF- $\kappa$ B-mediated regulation of urokinase gene expression by PMA and TNF- $\alpha$ in human A549 cells. <i>FEBS Letters</i> , 1996, 393, 69-73.	2.8	22

#	ARTICLE	IF	CITATIONS
181	Characterisation of circulating chromogranin A in human cancer patients. British Journal of Cancer, 1996, 73, 924-932.	6.4	32
182	Antigenic Regions of Human Chromogranin A and their Topographic Relationships with Structural/Functional Domains. FEBS Journal, 1996, 235, 275-280.	0.2	37
183	Inverse Polymerase Chain Reaction for Cloning Complete Human Immunoglobulin Variable Regions and Leaders Conserving the Original Sequence. Analytical Biochemistry, 1996, 239, 107-109.	2.4	21
184	Production of Soluble Tumor Necrosis Factor Receptor Type I in Escherichia coli: Optimization of the Refolding Yields by a Microtiter Dilution Assay. Analytical Biochemistry, 1995, 230, 85-91.	2.4	11
185	Identification of Two Forms (31-33 and 48 kD) of the Urinary Soluble p55 Tumor Necrosis Factor Receptor That Are Differentially N- and O-Glycosylated. Journal of Interferon and Cytokine Research, 1995, 15, 143-152.	1.2	14
186	Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure. Circulation, 1995, 92, 1479-1486.	1.6	452
187	Tumor Necrosis Factor (TNF) $\hat{\pm}$ quantification by ELISA and bioassay: effects of TNF $\hat{\pm}$ -soluble TNF receptor (p55) complex dissociation during assay incubations. Journal of Immunological Methods, 1994, 177, 191-198.	1.4	67
188	Idiotope determining regions of a mouse monoclonal antibody and its humanized versions. Journal of Molecular Biology, 1994, 235, 53-60.	4.2	8
189	PCR amplification of antibody variable regions using primers that anneal to constant regions. Nucleic Acids Research, 1994, 22, 1768-1769.	14.5	4
190	Evidences that syngeneic alpha-type anti-idiotypic antibodies may non-competitively inhibit idiotype/oligomeric antigen interactions by affecting idiotype avidity. Molecular Immunology, 1993, 30, 1123-1131.	2.2	2
191	Kinetic analysis of TNF- $\hat{\pm}$ oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine, 1993, 5, 539-545.	3.2	26
192	Mode of Interaction Between Tumor Necrosis Factor $\hat{\pm}$ and a Monoclonal Antibody Expressing a Recurrent Idiotype. Hybridoma, 1993, 12, 1-13.	0.6	6
193	Oligomeric tumour necrosis factor $\hat{\pm}$ slowly converts into inactive forms at bioactive levels. Biochemical Journal, 1992, 284, 905-910.	3.7	117
194	Antigenic regions of tumor necrosis factor alpha and their topographic relationships with structural/functional domains. Molecular Immunology, 1992, 29, 471-479.	2.2	8
195	Mode of interaction between a monoclonal antibody and human TNF $\hat{\pm}$ . Pharmacological Research, 1992, 26, 144-145.	7.1	0
196	Binding of human tumor necrosis factor $\hat{\pm}$ to multimeric complementary peptides. Archives of Biochemistry and Biophysics, 1992, 296, 137-143.	3.0	26
197	Affinity enhancement of complementary peptide recognition. International Journal of Peptide and Protein Research, 1992, 39, 549-556.	0.1	22
198	Rapid and simple DNA detection by hybridization on absorbent filters. Nucleic Acids Research, 1991, 19, 1351-1351.	14.5	3

#	ARTICLE	IF	CITATIONS
199	A rapid method for monitoring DNA labelling reactions with haptens. <i>Journal of Immunological Methods</i> , 1990, 134, 81-86.	1.4	2
200	Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin. <i>Journal of Hospital Infection</i> , 1986, 7, 85-89.	2.9	30
201	Autocrine saturation of pro-urokinase receptors on human A431 cells. <i>Cell</i> , 1986, 45, 675-684.	28.9	364
202	Purification and Characterization of Single-Chain Urokinase-Type Plasminogen Activator (Pro-Urokinase) from Human A431 Cells. <i>Thrombosis and Haemostasis</i> , 1986, 56, 219-224.	3.4	21
203	Differential Detection of Single-Chain and Two-Chain Urokinase-Type Plasminogen Activator by a New Immunoabsorbent-Amidolytic Assay (IAA). <i>Thrombosis and Haemostasis</i> , 1986, 56, 407-410.	3.4	11
204	Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 4939-4943.	7.1	427
205	Synthesis and characterization of D-Alanyl-D-Alanine-Agarose. <i>Applied Biochemistry and Biotechnology</i> , 1985, 11, 101-109.	2.9	44
206	Teicoplanin, a new antibiotic from <i>Actinoplanes teichomyceticus</i> nov. sp. <i>Antimicrobial Agents and Chemotherapy</i> , 1984, 26, 917-923.	3.2	118
207	Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984, 81, 110-114.	7.1	35
208	Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. <i>Oncotarget</i> , 0, 7, 41725-41736.	1.8	9